Drug Farm, currently in the clinical phase, has shared the news of the first participant in the Phase 1 clinical experiment, testing DF-003, receiving their initial dosage.

The study on Atrial Fibrillation using Abelacimab was prematurely ended by the Data Monitoring Committee due to a massive decrease in bleeding compared to a DOAC.

LinKinVax and Gustave Roussy have reported that Gustave Roussy is treating the initial participant in a Phase I/IIa clinical trial using CD40HVac.

Artificial intelligence-focused Lantern Pharma Inc unveiled the FDA's approval of their IND application for LP-284.

Otsuka Pharmaceutical Europe Ltd. and Astex Pharmaceuticals, Inc. announced EC's approval of INAQOVI® for treating newly diagnosed acute myeloid leukaemia in adults unfit for standard induction chemotherapy.

Atamyo Therapeutics made public its submission of a CTA for ATA-200 in European territories.

BeiGene, Ltd. revealed that TEVIMBRA®(tislelizumab) has received approval by the EC to be used as a single therapy for addressing unresectable.

ESSA Pharma Begins Phase 2 trial of Masofaniten (EPI-7386) in Combination with Enzalutamide for Patients Suffering from Metastatic Castration-Resistant Prostate Cancer.

FDA Prioritizes Review of Merck's Additional New Drug Submission for WELIREG® (belzutifan) for Previously Treated Patients with Advanced Renal Cell Carcinoma.

Pfizer Inc. confirmed the received marketing approval by the EC for LITFULO™ (ritlecitinib)  aimed for the treatment of severe alopecia areata in adults and adolescents aged 12 years and above.

Heidelberg Pharma AG announced it began patient recruitment for the fifth group in the Phase I/IIa trial of their main development candidate, HDP-101, with a dose of 100 µg/kg.

Orexo AB recently submitted its NDA to the US FDA for OX124, a high-dose, nasally-administered treatment for opioid overdoses.